Novelion Therapeutics Inc (NVLNF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2008 | 12-2007 | 12-2006 | 12-2005 | 12-2004 | |
| Sales | 124,140 | 127,900 | 175,090 | 241,970 | 186,070 |
| Cost of Goods | 53,920 | 48,220 | 42,190 | 51,230 | 33,370 |
| Gross Profit | 70,210 | 79,670 | 132,890 | 190,740 | 152,690 |
| Operating Expenses | 55,120 | 80,550 | 105,080 | 113,290 | 72,440 |
| Operating Income | 16,020 | -650 | 28,010 | 77,680 | 80,630 |
| Interest Expense | 10,330 | 9,020 | 6,590 | 6,350 | 6,260 |
| Other Income | 18,780 | -136,640 | -95,800 | -408,140 | -223,140 |
| Pre-tax Income | 24,470 | -146,310 | -74,380 | -336,810 | -148,770 |
| Income Tax | 9,520 | -36,570 | 9,030 | -11,400 | 29,440 |
| Net Income Continuous | -2,100 | 12,264 | 29,085 | 61,838 | 36,774 |
| Net Income Discontinuous | 119,930 | -260 | -18,190 | 0 | 0 |
| Net Income | $134,890 | $-109,990 | $-101,600 | $-325,410 | $-178,220 |
| EPS Basic Total Ops | 9.05 | -7.35 | -6.00 | -17.55 | -11.30 |
| EPS Basic Continuous Ops | -0.14 | 0.82 | 1.72 | 3.34 | 2.51 |
| EPS Basic Discontinuous Ops | 8.04 | -0.02 | -1.08 | N/A | N/A |
| EPS Diluted Total Ops | 9.05 | -7.35 | -6.00 | -17.55 | -11.30 |
| EPS Diluted Continuous Ops | -0.14 | 0.82 | 1.72 | 3.34 | 2.51 |
| EPS Diluted Discontinuous Ops | 8.04 | -0.02 | -1.08 | N/A | N/A |
| EBITDA(a) | $19,810 | $7,350 | $36,390 | $93,820 | $86,250 |